|

Long-term Follow up Local Registry Study of Kymriah in South Korea

RECRUITINGSponsored by Novartis Pharmaceuticals
Actively Recruiting
SponsorNovartis Pharmaceuticals
Started2025-03-12
Est. completion2039-12-30
Eligibility
Age0 Years – 100 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06785818

Summary

This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.

Eligibility

Age: 0 Years – 100 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Patients who receive tisagenlecleucel infusion in the commercial setting, treated under a managed access program or other pathway, e.g., when product was manufactured for the commercial setting but turned out to be out of specification (OOS).
2. Consented to data collection.

Exclusion Criteria:

1\. Patients who are enrolled or will be enrolled in the Novartis long term follow-up protocol CCTL019A2205B.

Conditions2

B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular LymphomaCancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.